Immunotherapies are undoubtedly transforming the landscape of cancer treatment worldwide. By harnessing the body's immune ...

Today, the U.S. House of Representatives passed a Congressional Review Act Resolution of Disapproval (CRA) to repeal an important air pollution rule.

Final overall survival (OS) results from the INAVO120 trial (NCT04191499) confirmed that the addition of inavolisib (Itovebi) ...

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified adenocarcinoma-like ...

Common cancer symptoms like lumps are rarely associated with a Stage 0 cancer diagnosis – meaning they're almost exclusively ...

The Pathology Department of Ongole Government General Hospital (GGH) and Medical College on Monday has launched advanced ...

Standard medical practice is to not test men who have a life expectancy of less than 10 years for prostate cancer.

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified ...

Background and objectives Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer.

(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of ...

Cell.Ai, a precision oncology company developing advanced cell and molecular profiling platforms, announced the successful completion of a CLIA-grade analytical validation study of its OncoIncytes ...